Acute Poisonings from Synthetic Cannabinoids — 50 U.S. Toxicology Investigators Consortium Registry Sites, 2010–2015

Anne M. Riederer, ScD1; Sharan L. Campleman, PhD1; Robert G. Carlson, PhD2; Edward W. Boyer, MD, PhD3; Alex F. Manini, MD4; Paul M. Wax, MD1,5; Jeffrey A. Brent, MD, PhD1,6; Toxicology Investigators Consortium (ToxIC)

Recent reports suggest that acute intoxications by synthetic cannabinoids are increasing in the United States (1,2). Synthetic cannabinoids, which were research compounds in the 1980s, are now produced overseas; the first shipment recognized to contain synthetic cannabinoids was seized at a U.S. border in 2008 (3). Fifteen synthetic cannabinoids are Schedule I controlled substances (3), but enforcement is hampered by the continual introduction of new chemical compounds (1,3). Studies of synthetic cannabinoids indicate higher cannabinoid receptor binding affinities, effects two to 100 times more potent than Δ⁹-tetrahydrocannabinol (the principal psychoactive constituent of cannabis), noncannabinoid receptor binding, and genotoxicity (4,5). Acute synthetic cannabinoid exposure reportedly causes a range of mild to severe neuropsychiatric, cardiovascular, renal, and other effects (4,6,7); chronic use might lead to psychosis (6,8). During 2010–2015, physicians in the Toxicology Investigators Consortium (ToxIC) treated 456 patients for synthetic cannabinoid intoxications; 277 of the 456 patients reported synthetic cannabinoids as the sole toxicologic agent. Among these 277 patients, the most common clinical signs of intoxication were neurologic (agitation, central nervous system depression/coma, and delirium/toxic psychosis), with seizures and hallucinations accompanying friends and family members were K2 and Spice. In 415 (91.0%) cases, the patient had clinical signs of intoxication; specific toxicologic treatments were administered to 267 (58.6%) patients, whereas the rest received standard supportive care and monitoring before being discharged. No specific synthetic cannabinoid antidotes exist.

Temporal trends in the ToxIC synthetic cannabinoid case entries were investigated. Mixed logistic regression was used to evaluate the association between year and annual percentage of synthetic cannabinoid cases (among total cases, any agent), by site. The lme4 package in R (R Foundation for Statistical Computing, Vienna, Austria) was used to fit the model, accounting for intra-site and intragroup (e.g., participants in ToxIC’s designer drug subregistry) correlation. To evaluate model fit, a deviance test was conducted, comparing the full model to a reduced model without the year variable. Sensitivity analyses were also conducted by dropping one site at a time and refitting the model.

During January 1, 2010–November 30, 2015, a total of 42,138 cases of toxic exposure were logged by 101 participating hospitals and clinics (Figure 1). Among these, 456 cases (at 50 ToxIC sites) involved synthetic cannabinoids, either as the sole toxicologic agent (n = 277) or as a component of a multiagent exposure (n = 179). Although most sites reported <20 synthetic cannabinoid cases, large sites in Harrisburg, Pennsylvania, New York City, Phoenix, Arizona, and Rochester, New York each recorded ≥30 synthetic cannabinoid intoxication cases. In contrast, during the same period, only 13 cases were logged by ToxIC involving nonsynthetic cannabinoids (i.e., cannabis) as the sole toxicological agent; among these, the majority (n = 11) were children (aged 2–6 years) or teenagers (age 13–18 years).

Among all 456 synthetic cannabinoid intoxication cases, 322 (70.6%) occurred in persons aged 19–65 years and 125 (27.4%) occurred in persons aged 13–18 years; 379 (83.1%) patients were male. The most common street names of synthetic cannabinoids reported by patients or accompanying friends and family members were K2 and Spice. In 415 (91.0%) cases, the patient had clinical signs or symptoms of intoxication; specific toxicologic treatments were administered to 267 (58.6%) patients, whereas the rest received standard supportive care and monitoring before being discharged. No specific synthetic cannabinoid antidotes exist.

Among the 277 (61%) patients who reported synthetic cannabinoids as the sole toxicologic exposure, the system most commonly affected was the central nervous system (Table), manifested by agitation, central nervous system depression/coma, and delirium/toxic psychosis, with seizures and hallucinations reported less frequently. Information on death during hospitalization was available for 246 (54%) patients. Among these, three (1.2%) deaths were recorded. The first occurred in...
a male aged 17 years, who suffered a cardiac arrest after reportedly taking a single “hit” of K2/Spice; the second occurred in an adult male with respiratory depression, agitation, and delirium/toxic psychosis after allegedly taking a synthetic cannabinoid and oxycodone; and the third occurred in an adult male with similar signs, who developed acute kidney injury after reportedly taking a synthetic cannabinoid, a synthetic cathinone (commonly known as bath salts), and the psychedelic drug lysergic acid diethylamide (LSD).

During 2010–2015, the annual percentage of synthetic cannabinoid cases among sites increased in all four U.S. Census regions; during 2014–2015, the annual percentage increased in all regions except the South (Figure 2). The largest overall increases during these periods took place in the Northeast, primarily driven by increases at the New York City sites. Less distinct but discernable increases occurred at sites in several other cities nationwide, and a decrease occurred at the Rochester, New York, site; heterogeneous patterns occurred elsewhere (not shown). In the mixed regression analysis, the deviance test indicated that including year in the model provided a significantly (p<0.05) better fit, evidence of a statistically significant temporal trend. In the sensitivity analyses, including the year variable improved model fit in a statistically significant manner, in each iteration (i.e., when the model was refit after dropping one site at a time).

**FIGURE 1.** Toxicology Investigators Consortium (ToxIC)* registry cases caused by all agents and by synthetic cannabinoid,† by U.S. registry site location§ — January 1, 2010–November 30, 2015

**TABLE.** Percentage of patients (n = 277) reporting synthetic cannabinoids as the sole toxicologic agent* among 42,138 cases of toxic exposure reported at 101 participating hospitals and clinics, by clinical sign or symptom — Toxicology Investigators Consortium (ToxIC) registry, January 1, 2010–November 30, 2015

<table>
<thead>
<tr>
<th>Organ system/Syndrome</th>
<th>Clinical sign/symptom</th>
<th>Patients reporting SC as sole agent (%)†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nervous</td>
<td>Agitation, coma, toxic psychosis, other</td>
<td>66.1</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>Bradycardia, tachycardia, other</td>
<td>17.0</td>
</tr>
<tr>
<td>Pulmonary</td>
<td>Respiratory depression</td>
<td>5.4</td>
</tr>
<tr>
<td>Other</td>
<td>Acute kidney injury</td>
<td>4.0</td>
</tr>
<tr>
<td>Renal/Muscle</td>
<td>Rhabdomyolysis</td>
<td>6.1</td>
</tr>
<tr>
<td>Other</td>
<td>Metabolic</td>
<td>8.7</td>
</tr>
<tr>
<td>Other</td>
<td>Gastrointestinal/Hepatic</td>
<td>1.4</td>
</tr>
<tr>
<td>Other</td>
<td>Significant leukocytosis</td>
<td>2.9</td>
</tr>
<tr>
<td>Toxidrome</td>
<td>Sedative-hypnotic</td>
<td>6.9</td>
</tr>
<tr>
<td>Other</td>
<td>Sympathomimetic syndrome</td>
<td>5.4</td>
</tr>
<tr>
<td></td>
<td>Other</td>
<td>2.2</td>
</tr>
</tbody>
</table>

Abbreviation: SC = synthetic cannabinoid.

* A total of 456 reported cases (at 50 ToxIC sites) involved synthetic cannabinoids, either as the sole toxicologic agent (n = 277) or as a component of a multiagent exposure (n = 179).
† Percentages do not sum to 100% because some patients had more than one clinical sign.

* ToxIC is a select, volunteer network and thus not geographically representative of the United States or the cities where participating sites are located; many sites joined ToxIC after its establishment in 2010 by the American College of Medical Toxicology.
† As primary agent or part of multiagent exposure.
§ As of November 2015, there were active ToxIC registry sites in 41 U.S. cities, with a few cities (e.g., Boston and New York City) having multiple sites.
**FIGURE 2. Percentage of reported ToxIC* registry cases† caused by synthetic cannabinoids, by U.S. Census region — 2010, 2014, and 2015**

- **Northeast**
  - 2015 (through Nov 30)
  - 2014
  - 2010
- **Midwest**
  - 2015 (through Nov 30)
  - 2014
  - 2010
- **South**
  - 2015 (through Nov 30)
  - 2014
  - 2010
- **West**
  - 2015 (through Nov 30)
  - 2014
  - 2010

* ToxIC is a select, volunteer network and thus not geographically representative of the United States or the cities where participating sites are located; many sites joined ToxIC after its establishment in 2010 by the American College of Medical Toxicology.
† Includes only cases from sites that reported any synthetic cannabinoid cases.

**Discussion**

The ToxIC data complement data from health agencies, poison centers, and other sources to produce a more detailed picture of the acute public health impacts of synthetic cannabinoid use in the United States. Although some potential for report overlap exists, cases in the ToxIC Registry are not routinely reported to poison centers. The significant increase in synthetic cannabinoid poisonings identified through this consortium reflects recent trends, which include a Drug Enforcement Agency report of 22 synthetic cannabinoid clusters (including two deaths) and 25 additional episodes (including 18 deaths) in 25 states during August 2011–April 2015 (1), as well as a 330% increase in synthetic cannabinoid–related calls to U.S. poison centers during the first 4 months of 2015 (2). The observed increases might result from increased synthetic cannabinoid use; the appearance of more toxic and potent synthetic cannabinoid compounds or multisynthetic cannabinoid formulations; increased recognition of synthetic cannabinoids as a cause of acute poisoning; increased familiarity among medical personnel with the clinical signs and symptoms of synthetic cannabinoids; or a combination of these factors (6,7).

The findings in this report are subject to at least five limitations. First, although ToxIC is a unique tool, it is clinically based, not population-based, and thus is not geographically representative of the United States or the cities where participating sites are located. The consortium includes most U.S. medical toxicology clinical services, but large areas of the country that do not have direct access to medical toxicologists are underrepresented. Second, although the consortium strives to report all cases treated by medical toxicologists at participating sites, reporting might be affected by several factors, including caseload, personnel changes, and referral patterns. Nonetheless, the consortium’s use of normalized statistics (the proportion of all consultations that were related to synthetic cannabinoids) and a mixed regression approach, which accounts for intrasite variability, improves confidence that the observed temporal increases are real. Third, synthetic cannabinoid case identification was based on patient history and clinical presentation; analytical confirmation is not available for most synthetic cannabinoid cases in the registry. The development of analytical tests that reliably detect synthetic cannabinoids and their metabolites in biologic samples is hindered by the production of new chemical compounds for which no analytical standards exist, difficulties in finding unique synthetic cannabinoid biomarkers, and other challenges (2,9,10); thus, analytical tests are not routinely used by every ToxIC physician. Instead, these physicians rely on patient self-reports or reports of accompanying family members or friends. Because of this, reports of drugs taken might be inaccurate, leading to misattribution of certain clinical signs and symptoms to synthetic cannabinoids. Fourth, as is common in drug abuse/misuse cases (8), approximately half of the ToxIC synthetic cannabinoid cases involved multiagent exposures, including synthetic cannabinoids in combination with other illicit or prescription drugs or alcohol. Consequently, other agents, or the combination of psychoactive substances, might have been responsible for the effects observed. A small German study, with analytical confirmation of the synthetic cannabinoids and other drugs in patient samples, reported that clinical signs in patients with concurrent drug exposures were similar to those who were exposed only to synthetic cannabinoids (7). Finally, patients occasionally declined to divulge details...
of their exposure. For example, among 37,984 total cases recorded at ToxIC’s U.S. sites during January 1, 2010–June 30, 2015, a total of 3,153 (8.3%) were missing agent information or recorded as unknown agent. Some of these cases possibly involved synthetic cannabinoids but were not recorded as such.

The increase in acute synthetic cannabinoid poisonings observed in ToxIC underscores the need for targeted prevention interventions. Educating the public on the potentially life-threatening consequences of synthetic cannabinoid use is important for countering the observed upward trend in synthetic cannabinoid poisonings.

Acknowledgments
Toxicology Investigators Consortium members and personnel.

1. ToxIC, American College of Medical Toxicology, Phoenix, Arizona; 2. Boonshoft School of Medicine, Wright State University, Dayton, Ohio; 3. University of Massachusetts Medical School, Worcester, Massachusetts; 4. Division of Medical Toxicology, The Icahn School of Medicine at Mt. Sinai, New York, New York; 5. University of Texas Southwestern Medical Center, Dallas, Texas; 6. Department of Medicine, University of Colorado School of Medicine, Colorado School of Public Health, Aurora, Colorado.

Corresponding author: Anne M. Riederer, anne.riederer@acmt.net, 844-226-8333, ext. 710.

References